4家生物制药公司根据《纳斯达克规则》给予新雇员股票选择权,允许未经股东批准就给予引诱性奖励。 Four biopharma firms granted stock options to new hires under a Nasdaq rule allowing inducement awards without shareholder approval.

四家生物制药公司——Akebia治疗公司、Candel治疗公司、Protara治疗公司和X4药品公司——宣布向新雇员提供股票选择权赠款,援引Nasdaq Listing规则第5635(c)(4)条,该规则允许在无需股东批准的情况下为吸引人才而颁发奖励奖。 Four biopharmaceutical companies—Akebia Therapeutics, Candel Therapeutics, Protara Therapeutics, and X4 Pharmaceuticals—announced stock option grants to new employees, citing Nasdaq Listing Rule 5635(c)(4), which allows inducement awards to attract talent without requiring shareholder approval. 赠款是招聘工作的一部分,用于招聘新人员。 The grants are part of recruitment efforts and were made in connection with hiring new personnel.